Istanbullulab
istanbullulab.bsky.social
Istanbullulab
@istanbullulab.bsky.social
Medicinal chemistry lab @IKCU, Faculty of Pharmacy, Izmir.
Drug discovery studies; design and synthesis new compounds as antileishmanial, antibacterial, anticancer, antiparasitic, FABPi, TYK2i
@istanbulluh.bsky.social
@huseyinkosker.bsky.social
Reposted by Istanbullulab
Please RT:
We have an opening for a junior group leader position in „Phage Biology & Biotechnology“.
www.fz-juelich.de/de/karriere/...

Interested candidates are encouraged to contact me via email for further details.

@spp2330.bsky.social; @mibinet.bsky.social
Junior Group Leader - Phage Biology & Biotechnology
As a leading research institution for microbial biotechnology the Institute of Bio- and Geosciences - Biotechnology (IBG-1, https://www.fz-juelich.de/de/ibg/ibg-1 ) at the Forschungszentrum Jülich foc...
www.fz-juelich.de
October 8, 2025 at 6:50 AM
Reposted by Istanbullulab
Spreading the results of @costprogramme.bsky.social Action networks to different target audiences is crucial. That’s why we’re focusing this week on mastering social media. Starting today with our Science Communication Coordinators. Thanks to all for joining us for the #COSTAcademy training! 😊
September 29, 2025 at 2:51 PM
We're pleased to share our latest paper, published in Drug and Drug candidates titled "Probing Redox Responses and DNA Interactions in Drug Discovery"

@istanbulluh.bsky.social
@huseyinkosker.bsky.social
May 4, 2025 at 1:55 PM
Reposted by Istanbullulab
Our project entitled ‘Synthesis and biological activities of antimycobacterial effective pyrrolamide derivatives’has been entitled to support within the scope of TÜBİTAK 2209-A Research Projects Support Programme for Undergraduate Students 2024/1
@istanbulluh.bsky.social
@huseyinkosker.bsky.social
April 10, 2025 at 12:28 PM
Our project entitled ‘Synthesis and biological activities of antimycobacterial effective pyrrolamide derivatives’has been entitled to support within the scope of TÜBİTAK 2209-A Research Projects Support Programme for Undergraduate Students 2024/1
@istanbulluh.bsky.social
@huseyinkosker.bsky.social
April 10, 2025 at 12:28 PM
Reposted by Istanbullulab
We're excited to share our latest paper, published in ChemBiodiv titled ‘Novel Triazolopyrimidinone Compounds as Adipocyte Fatty Acid Binding Protein (FABP4) Inhibitors’
doi.org/10.1002/cbdv...

@istanbulluh.bsky.social
@huseyinkosker.bsky.social
March 19, 2025 at 4:14 PM
We're excited to share our latest paper, published in ChemBiodiv titled ‘Novel Triazolopyrimidinone Compounds as Adipocyte Fatty Acid Binding Protein (FABP4) Inhibitors’
doi.org/10.1002/cbdv...

@istanbulluh.bsky.social
@huseyinkosker.bsky.social
March 19, 2025 at 4:14 PM
Our project, submitted to the TUBITAK-2515 programme within the COST-CA21111 action "One Health drugs against parasitic vector borne diseases in Europe and beyond (OneHealthDrugs)", was eligible for funding.
@istanbulluh.bsky.social
@huseyinkosker.bsky.social
March 1, 2025 at 2:42 PM
Reposted by Istanbullulab
Looking for a PostDoc outside the UK to apply with me for a fully funded 2-year postdoc in electrosynthesis! #Newton
📩 No generic emails! Instead, tell me:
🔹 Your research & key contributions
🔹 How our expertise complements each other
Let’s chat! ⚡ RT & tag potential candidates! #ChemSky
February 22, 2025 at 12:06 PM
Reposted by Istanbullulab
The Hit to Lead process is an integral part of contemporary drug discovery.
A perspective just published in #ChemMedChem (@chemistryeurope.bsky.social), highlight the new set of @euromedchem.bsky.social best practices focused on H2L.
chemistry-europe.onlinelibrary.wiley.com/doi/10.1002/...
The European Federation for Medicinal Chemistry and Chemical Biology (EFMC) Best Practice Initiative: Hit to Lead
Best practices for the Hit-to-Lead phase of drug discovery are exemplified in this article, with links to further materials and references as a learning resource. This consensus output was produced b....
chemistry-europe.onlinelibrary.wiley.com
February 21, 2025 at 8:07 AM
Within the scope of TÜBİTAK-1001-2024-2; our project entitled "Synthesis of new thiazolopyrimidine pyrrolimide derivatives as DNA GyraseB inhibitor antibacterial agents and evaluation of their biological activities" was found eligible for support
@istanbulluh.bsky.social
@huseyinkosker.bsky.social
February 21, 2025 at 6:39 PM
Reposted by Istanbullulab
Join our research team!

We have a Postdoctoral Fellowship opening on diamond-based quantum networks.

Deadline is March 12th!

Follow the link for details!
#quantum #optics #spin #photon #physics #diamond #research #vacancy #postdoc

www.jobs.cam.ac.uk/job/50162/
Research Associate in Quantum Networks using Diamond Spin Qubits (Fixed Term) - Job Opportunities - University of Cambridge
Research Associate in Quantum Networks using Diamond Spin Qubits (Fixed Term) in the Department of Physics at the University of Cambridge.
www.jobs.cam.ac.uk
February 4, 2025 at 9:02 AM
Reposted by Istanbullulab
Postdoctoral Researcher on Quantum Networks using Diamond Spin Qubits, University of Cambridge

#QuantumNetworks #QuantumMemory #QuantumOptics

www.quantiki.org/position/pos...
Postdoctoral Researcher on Quantum Networks using Diamond Spin Qubits - University of Cambridge | Quantiki
www.quantiki.org
February 17, 2025 at 4:40 PM
Reposted by Istanbullulab
👀 In case you missed it...here’s a sneak peek into Guinea’s incredible journey to eliminate #SleepingSickness as a public health problem!

📽️ Watch the full film to see how Guinea achieved this milestone: youtube.com/watch?v=csdn...

#BeatNTDs
February 20, 2025 at 1:38 PM
Reposted by Istanbullulab
Very interesting to see the 50 new drugs that made it to FDA approval in 2024 in one place. A lot of really exciting small molecule chemistry with interesting functional groups, deuterations and covalent warheads. #chemsky #chembio
www.linkedin.com/posts/chrisd...
Chris De Savi on LinkedIn: #medicine #pharmaceuticals #healthcare | 90 comments
FDA Novel Drug Approvals 2024 #medicine That is a wrap for 2024! And another year of relentless drug discovery! There you have it, drug-hunting aficionados,… | 90 comments on LinkedIn
www.linkedin.com
January 3, 2025 at 9:00 AM
Reposted by Istanbullulab
A 2-yr postdoc is available in our group! The successful candidate will have a strong background in organic synthesis and <6 years after a PhD. The research will focus on novel mechanochemical organic reactions. Questions/applications: email Lukasz (address in the pic). Deadline: 7th March 2025.
February 14, 2025 at 5:35 PM
Reposted by Istanbullulab
New PhD/PostDoc positions in Machine Learning for Quantum Computing and Simulation of Quantum Matter:
dobrautz.github.io/jobs/postdoc...
dobrautz.github.io/jobs/phd/cas...

Sharing and endorsing would be really appreciated <3

@hzdr.bsky.social @scadsai.bsky.social @tudresden.bsky.social
Postdoc (f/m/d) | Werner Dobrautz
PostDoc in Machine Learning for Quantum Computing and Simulation of Quantum Matter
dobrautz.github.io
January 24, 2025 at 10:04 PM
Reposted by Istanbullulab
Who wants to come and work with our group @oxfordchemistry.bsky.social on photoswitches and photopharmacology 🙋‍♀️🙋🏻🙋‍♂️

Apply for our open #chempostdoc position now! Deadline 28th Feb. Reposts appreciated #Chemsky

my.corehr.com/pls/uoxrecru...
a beam of green light is shining on a black background
ALT: a beam of green light is shining on a black background
media.tenor.com
January 30, 2025 at 6:25 PM
Reposted by Istanbullulab
#PostDoc opportunity in synthesis of small ring hydrocarbons and heterocycles at University of Oxford (UK) ref: 177884 | duration: 48 months | start: before 01-Jul-2025 | closing: 02-Mar-2025 #SynChem #ChemPostDoc #PostDocJobs #UKChemJobs #chemsky 🧪
my.corehr.com/pls/uoxrecru...
Job Details
my.corehr.com
February 6, 2025 at 1:35 PM
Reposted by Istanbullulab
Exciting Opportunity Alert! Join our team as a Postdoc in Molecular Biology/ Biochemistry/ Analytical Chemistry at the University of Copenhagen, on a new project funded by the Novo Nordisk Foundation 🧪🧬 🌱
Apply here: tinyurl.com/sbf8szjc
#AcademicJobs #ScienceCareers #researchJobs #Postdoc
Postdoctoral Researcher in Molecular Biology, Biochemistry and Analytical Chemistry
tinyurl.com
February 6, 2025 at 2:32 PM
Reposted by Istanbullulab
Boehringer's investigational idiopathic pulmonary fibrosis (IPF) drug nerandomilast had a "second phase 3 win" leading the company to expand the indications it will seek FDA approval for. FIBRONEER-ILD trial for progressive pulmonary fibrosis (PPF): www.fiercebiotech.com/biotech/boeh... #medsky
February 10, 2025 at 8:14 PM
Reposted by Istanbullulab
Our first contribution in J. Med. Chem; does this make us bona fide med chemists now? Check out this latest study on countering Parkinsonism by Drs. @rahuldjana.bsky.social, Nguyen, and Yan, and Prof. Chen!

Link: pubs.acs.org/doi/10.1021/...
January 4, 2025 at 4:28 PM
Reposted by Istanbullulab
If you work in drug discovery and you read one thing this weekend, make it this exceptional J Med Chem editorial. Hits on almost every blessed thing I’ve tweetorialized over the last several years.

Quantitation and Error Measurements in Dose–Response Curves
Quantitation and Error Measurements in Dose–Response Curves
pubs.acs.org
January 31, 2025 at 6:30 PM
Reposted by Istanbullulab
In 2007, John Van Drie wrote a very insightful article about what the fields of drug discovery and CADD might hold for us in the next 20 years. Since we are almost at the 20-year mark, I assess how well those predictions have held up (promisingly, I think) medchemash.substack.com/p/drug-disco...
Drug discovery and modeling: The view from 2007
In 2007, John Van Drie (ex-Vertex and Novartis) wrote a very insightful article on the future of molecular modeling and drug discovery.
medchemash.substack.com
January 31, 2025 at 8:57 PM
Reposted by Istanbullulab
Concluding remarks by Claudia Höbartner at #EFMCISCB25. Thanks to sponsors, exhibitors, committees, secretariat and, above all, participants that made this event a very successful one. See you again in 2027!
@euromedchem.bsky.social
@youngscinet.bsky.social
January 31, 2025 at 11:14 PM